TELCOR POC Device Connectivity Updates - Q4 2025
Lincoln, NE – February 17, 2026
The U.S. Food and Drug Administration (FDA) formally rescinded its final rule regulating laboratory-developed tests as medical devices, and regulatory review is now pending. Because the FDA did not move to appeal this decision, the rescission is essentially a formality.
The recission comes following the decision filed March 31 in the U.S. District Court in the Eastern District of Texas, which ruled the FDA exceeded its authority and subsequently vacated the final rule. The FDA did not appeal this decision.
Once the Office of Information and Regulatory Affairs completes the regulatory review, a formal notice will be posted to the Federal Register within 60 days.
Sources:
https://www.reginfo.gov/public/do/eoDetails?rrid=1044563
https://documents.cap.org/documents/ldt-courtruling-03-31-2025.pdf
https://www.cap.org/advocacy/latest-news-and-practice-data/august-12-2025#story3

Lincoln, NE – February 17, 2026
Company Recognized for Ongoing Commitment to Culture, Performance, and Innovation Lincoln, Nebraska – February 16,2026 – TELCOR Inc is proud to...
President Donald Trump signed the Consolidated Appropriations Act of 2026 (H.R.7148) into law on Feb. 3, delaying Medicare Clinical Laboratory Fee...